Single inhaler therapy with budesonide/formoterol [Symbicort SiT] provides greater asthma control than a higher dosage of budesonide plus terbutaline rescue, according to results from two phase III studies presented at the 60th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) [San Francisco, US; March 2004]. In the first study, morning peak expiratory flow (PEF) was significantly increased in budesonide/formoterol recipients, compared with patients given budesonide plus terbutaline. Furthermore, a significant 70% reduction in the risk of severe exacerbations was achieved among budesonide/formoterol, compared with budesonide plus terbutaline, recipients. In the second study, patients with moderate-to-severe asthma had a 39% lower risk of severe exacerbations when receiving budesonide/formoterol than when treated with budesonide plus terbutaline.